-
Amgen and Sanofi: What Does It Take To Patent An Antibody?Publications -
Time to reward innovation!Publications -
Mark Cohen, David Loewenstein and Leslie Kushner Named 2019 New York Metro Super LawyersAwards -
Pearl Cohen represents Orgenesis, Inc. in its Reorganization of Its Israel and Korea SubsidiariesPublications -
Humanigen Secures Exclusive Worldwide License for the Prevention of GvHD through GM-CSF Neutralization from the University of ZurichGeneral -
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) with lenzilumab in Relapsed/Refractory Diffuse Large B-Cell LymphoGeneral
-
Pearl Cohen Sponsors The Mitochondrial Biogenesis and Dynamics in Health and Disease ConferencePublications -
Orgenesis strikes deal with Columbia University to develop Cellular Vaccination product platformPublications -
Orgenesis Inc. (NASDAQ: ORGS) Announces Collaboration with Digilab, Inc.Publications -
Stelexis Therapeutics Closes $43 millionPublications -
Event Alert 15 January, 2019: BioMed MBA Meetup #6General -
Ayala Pharmaceuticals, Inc. entered into an option to license agreement with NovartisPublications